The Accumulation and Effects of Liposomal Doxorubicin in Tissues Treated by Radiofrequency Ablation and Irreversible Electroporation in Liver: In Vivo Experimental Study on Porcine Models

摘要

PurposeTo compare the accumulation and effect of liposomal doxorubicin in liver tissue treated by radiofrequency ablation (RFA) and irreversible electroporation (IRE) in in vivo porcine models.Materials and MethodsSixteen RFA and 16 IRE procedures were performed in healthy liver of two groups of three pigs. Multi-tined RFA parameters included: 100W, target temperature 105 degrees C for 7min. 100 IRE pulses were delivered using two monopolar electrodes at 2250V, 1Hz, for 100 mu sec. For each group, two pigs received 50mg liposomal doxorubicin (0.5mg/kg) as a drip infusion during ablation procedure, with one pig serving as control. Samples were harvested from the central and peripheral zones of the ablation at 24 and 72h. Immunohistochemical analysis to evaluate the degree of cellular stress, DNA damage, and degree of apoptosis was performed. These and the ablation sizes were compared. Doxorubicin concentrations were also analyzed using fluorescence photometry of homogenized tissue.ResultsRFA treatment zones created with concomitant administration of doxorubicin at 24h were significantly larger than controls (2.50.3cm vs. 2.2 +/- 0.2cm; p=0.04). By contrast, IRE treatment zones were negatively influenced by chemotherapy (2.2 +/- 0.4cm vs. 2.6 +/- 0.4cm; p=0.05). At 24h, doxorubicin concentrations in peripheral and central zones of RFA were significantly increased in comparison with untreated parenchyma (0.431 +/- 0.078 mu g/g and 0.314 +/- 0.055 mu g/g vs. 0.18 +/- 0.012 mu g/g; p<0.05). Doxorubicin concentrations in IRE zones were not significantly different from untreated liver (0.191 +/- 0.049 mu g/g and 0.210 +/- 0.049 mu g/g vs. 0.18 +/- 0.012 mu g/g).Conclusionsp id=Par4Whereas there is an increased accumulation of periprocedural doxorubicin and an associated increase in ablation zone following RFA, a contrary effect is noted with IRE. These discrepant findings suggest that different mechanisms and synergies will need to be considered in order to select optimal adjuvants for different classes of ablation devices.